A cDNA clone encoding CENP-B, the 80-kDa human centromere autoantigen, was used to construct a panel of hybrid proteins containing four different regions of CENP-B. These have allowed us to identify three independent epitopes on CENP-B that are targets of autoantibodies. Two of these are recognized concurrently in -90% of patient sera containing anticentromere autoantibodies (ACA), conclusively demonstrating that this autoimmune response is polyclonal. When present and previous data are combined, ACA are shown to recognize at least five independent epitopes on CENP-B. A radioimmunoassay based on cloned CENP-B has demonstrated that sera from 296% of patients with ACA recognize the cloned antigen, thus defining a region of the protein that is recognized by virtually all patients with ACA. These rmdings have significant implications for models that seek to explain the origin of ACA and for the future detection of this group of autoantibodies in the clinical setting.
The rheumatic diseases are characterized by the production of autoantibodies directed against nuclear and cytoplasmic autoantigens (reviewed in refs. [1] [2] [3] [4] [5] [6] [7] [8] . The reasons for autoantibody expression are generally unknown, and many theories seeking to explain the phenomenon are currently under consideration. In particular, it is not known if the autoimmune response results from a classical antigen-driven immunization or is a result of aberrations of the mechanisms that normally control the immune system.
We have chosen the anticentromere autoantibody (ACA) response for study since this involves the production of high-titer, high-affinity autoantibodies that recognize protein antigens. ACA were discovered in 1980, when it was found that certain patients with the calcinosis/Raynauds phenomenon/esophogeal dysmotility/sclerodactyly/telangiectasiae (CREST) variant of scleroderma produce autoantibodies that recognize the centromere region of chromosomes (9) (10) (11) . Though ACA are closely associated with the CREST syndrome, the only clinical finding common to all ACA+ individuals is Raynauds phenomenon (12) .
Our prior immunoblotting analysis revealed that >96% of a test group of 39 ACA+ sera recognized three chromosomal polypeptides of 17 kDa (CENP-A), 80 kDa (CENP-B), and 140 kDa (CENP-C) (refs. 12 and 13; see also refs. [14] [15] [16] [17] [18] [19] . Antibodies affinity purified from CENP-B cross-reacted with CENPs A and C, indicating that these antigens are structur ally related (13) . Antibodies to CENP-B are present at high titer in all ACA+ sera examined, whereas the titer of antibodies to CENPs A and C is occasionally lower (12) .
We describe below a detailed examination of the binding of ACA to subdomains of CENP-B that have been cloned and expressed in bacteria. Our experiments reveal that the autoimmune response against this protein is multifocal: as many as five distinct determinants are recognized. Contrary to our prior expectations, the data suggest that ACA arise from a specific polyclonal immune response directed against centromeres.
MATERIALS AND METHODS
General Methods. All cloning methods and procedures have been described in detail elsewhere (20) . NaDodSO4/ PAGE was performed using the method of Lewis and Laemmli (21) . Electrophoretic transfer of proteins to nitrocellulose (22) was performed at 340 mA for 6 hr at 4°C. The immunoblotting protocol has been described (12) , as has the method for affinity purification of antibodies from nitrocellulose strips (13) . The antibody-blocking experiments were described in ref. 20 .
RIA. Fusion protein granules were isolated by differential centrifugation from induced (23, 24) cultures of lysogen X-CENP-B1 (20, 36) . Granules were then solubilized in hot urea and dialyzed into 10 mM Tris-HCl, pH 7.7/50 mM NaCl/2 mM EDTA. The yield was 1 mg of Cte,,nCENP-B[, 8-gal] per liter of bacterial culture. CtlmCENP-B[p-gal] in 10 mM imidazole buffer was adsorbed to microtiter plates (0.1 ,ug per well; Removawell strips, Immulon) that were then probed with a 1:500 dilution of patient serum followed by 1251I-labeled protein A; radioactivity was determined in a y counter as described (25) . All assays were performed in triplicate and sera were used in random order.
RESULTS
Molecular Cloning of CENP-B. We previously obtained a series ofoverlapping cDNA clones corresponding to =95% of the mRNA encoding CENP-B (20 (12) .] Remarkably, all 37 ACA' sera bound significantly to CtermCENP-B (Fig. 1A) . Strong binding was evident for 86% (32 sera) and weaker binding characterized the remaining 14% (5 sera). Control sera (lanes 12, 18, and 40) did not bind the cloned antigen.
In our previous studies of cloned CENP-B, we isolated a murine monoclonal antibody, m-ACA1, that recognizes a site (CE1) present in CtermCENP-B (20) . We now show that the site recognized by m-ACA1 overlaps a major autoepitope on CENP-B. Nitrocellulose blots containing CtermCENP-B were cut into 40 strips, each ofwhich was incubated overnight with a 1:50 dilution of human serum. Each strip was then probed with m-ACA1, the binding of which was detected with 125I-labeled goat anti-mouse IgG ( 1C ). Sera 6 and 9 recognized this hybrid protein (and a proteolytic fragment) strongly, whereas weaker binding was exhibited by sera 3, 13, 19, 24, 32, and 38 (making 22% in all). The location of CE2 was defined by a second murine monoclonal antibody, m-ACA2, previously shown to bind to CtermCENP-BL, (20) . Three patient sera showed significant blocking of the binding of m-ACA2 (Fig. 1E , lanes 6, 9, and 19). The other five sera that bound to CtermCENP-BL in immunoblots failed to block the binding of m-ACA2 to a significant degree, perhaps due to low titers of anti-CE2 antibodies.
Even though all ACA' sera bound to CtermCENP-B, only a handful (22%) recognized CtemCENP-BL and none recog- were subjected to NaDodSO4/PAGE and immunoblotting (Fig. 1A) . The region of the nitrocellulose containing the fusion protein with its bound autoantibody and 1251-labeled protein A was excised and counted in a y counter. The results for the panel of 40 sera are shown in Fig. 4B along with (Fig. 4B) , it is likely that CE1 is the principal determinant being recognized in the RIA. CE1 is recognized by virtually all ACA' patient sera previously identified by indirect immunofluorescence.
CE2 is located within a 104 amino acid stretch starting 43 amino acids upstream from the carboxyl terminus of CENP-B. This epitope is recognized by only =20% of the patient sera tested, and, even in the sera that interact most significantly with it (Fig. 1C, lanes 6 and 9) , anti-CE2 comprises only a small fraction of the antibodies that recognize CtermCENP-B.
CE3 is located somewhere within the amino-terminal 60% of CENP-B. It is strongly recognized by a minority of ACA+ sera, but lower titers of anti-CE3 ACA are present in most (or all) of the remaining ACA+ sera. Overall, -90% of the ACA+ sera exhibit detectable binding to CE3. CE1 and CE3 are distinct structural determinants, since affinity-purified anti-CE1 and anti-CE3 do not cross-react (20) . shown. The precise location of the epitope within a given shaded segment is not known. aa, Amino acids. Chromosomal antigens: These determinants are defined by our earlier studies (13) . None of them is present on cloned CENP-B, although epitopes 4 and 5 are present on chromosomal CENP-B (13). None of these determinants has been precisely mapped.
Three additional autoepitopes recognized by ACA were previously identified by analysis of the binding of various affinity-purified patient sera to chromosomal antigens in immunoblots (13) . The first of these, CE4, is present on CENPs A and B and is absent from CENP-C (defined by sera GS and SN, ref. 13) . We demonstrated that -97% (38/39) of a panel of 39 ACA' patient sera had anti-CENP-A detectable by immunoblotting (12) . We assume that all sera binding to CENP-A bind to CE4, although the structure of this antigen may be more complex. Epitope CE5, shared by CENPs B and C, was defined by antibodies from serum JR, affinity-purified from CENP-C, that were subsequently found to cross-react strongly with CENP-B (13). Finally, CE6, found solely on CENP-C, was defined when antibodies were affinity purified from CENP-C (using serum GS) that showed no rebinding to CENP-B (13) . The pattern of binding observed using antibodies affinity purified from CE1, CE3, CE4, CE5, and CE6 indicates that all of these determinants are structurally independent (13, 20 Our data are inconsistent with all such models. These models could explain an autoimmune response against any single epitope, but they cannot account for the ACA response, since multiple structurally independent epitopes are targeted in virtually every affected individual (requiring multiple chance events).
Two of our observations presented above suggest that ACA might arise from an antigen-driven response. (i) Cloned CENP-B [unlike double-stranded DNA (32) ] is immunogenic in rabbits and mice (20) . [The Sm antigen (a marker antigen for systemic lupus erythematosus) is also immunogenic in rabbits and mice (33) .] (ii) ACA are polyclonal. Serum from single patients recognizes at least four independent epitopes on CENP-B. We have shown here that >90% of ACA+ sera recognize CE1 and CE3 and have shown elsewhere that .95% of the same sera also recognize CE4 and either CE5 or CE6 (12) . Thus, CENP-B appears to be the target of a diversified polyclonal response. This was postulated earlier to be true for anti-Sm (33, 34) and antiribonucleoprotein (35) autoantibodies, but in neither case was the conclusion confirmed by isolating multiple noncross-reactive specificities from patient serum.
In a recent review, Hardin (6) noted that most major autoantibodies found in systemic lupus erythematosus recognize nucleoprotein structures (small nuclear ribonucleoproteins, cytoplasmic ribonucleoproteins, and nucleosomes).
Our data suggest that ACA fit this pattern and that the ACA response may result from self immunization with centromeres. This is surprising, since centromeres are extremely minor cellular components and as such seem unlikely can-didates for the progenitors of a high-titer immune response (particularly since ACA occur in only a small fraction of the autoimmune patients who make antinuclear antibodies). Monoclonal antibody m-ACA1, which we have shown here to bind to a major autoepitope in CENP-B, should provide an important tool for future studies that attempt to locate the source of centromere antigen in affected individuals.
